Bharat Biotech

Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company's executive chairman Krishna Ella said on Sunday.

The company, in December 2022, got the approval for the primary 2-dose schedule, and as a heterologous booster dose.

Homegrown vaccine maker Bharat Biotech will launch its intranasal COVID-19 vaccine iNCOVACC, the first of its kind in India, on January 26.

Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received.

Bharat Biotech's nasal vaccine will cost Rs 800 plus taxes at private hospitals and slots can now be booked on the CoWin's portal, the pharmaceutical major has announced.

Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose for those aged 18 years and above and is likely to be introduced on the Co-WIN platform Friday evening, official sources said.

Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificate.

Bharat Biotech's needle-free intranasal Covid vaccine has been cleared for restricted use in emergency situations for those above the age of 18 years. iNCOVACC will become the first intranasal vaccine in the world.

Covid-19 vaccine Covaxin maker Bharat Biotech today said there was no external pressure on the firm to speed up its development.

Nearly 50 million doses of Bharat Biotech's COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said.

A nasal vaccine against Covid-19, iNCOVACC, developed by Bharat Biotech, has been approved by India's Central Drugs Standard Control Organisation. This is India's first intra-nasal vaccine against Covid-19

Union Health Minister Dr Mansukh Mandaviya tweets that it's "a big boost to India's Fight against Covid-19"

Bharat Biotech International Ltd (BBIL) on Monday said it has completed the phase-III and booster dose trials for its intranasal Covid-19 vaccine BBV154, and it has proven to be safe.

Bharat Biotech on Friday said Japan has approved Covaxin booster dosage for travellers visiting the country.

Bharat Biotech, which is working on an intranasal COVID-19 vaccine candidate is hopeful of getting regulatory licenses this month, if all goes well, Chairman and Managing Director of BBIL, Krishna Ella said.

Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company's executive chairman Krishna Ella said on Sunday.

The company, in December 2022, got the approval for the primary 2-dose schedule, and as a heterologous booster dose.

Homegrown vaccine maker Bharat Biotech will launch its intranasal COVID-19 vaccine iNCOVACC, the first of its kind in India, on January 26.

Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received.

Bharat Biotech's nasal vaccine will cost Rs 800 plus taxes at private hospitals and slots can now be booked on the CoWin's portal, the pharmaceutical major has announced.

Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose for those aged 18 years and above and is likely to be introduced on the Co-WIN platform Friday evening, official sources said.

Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificate.

Bharat Biotech's needle-free intranasal Covid vaccine has been cleared for restricted use in emergency situations for those above the age of 18 years. iNCOVACC will become the first intranasal vaccine in the world.

Covid-19 vaccine Covaxin maker Bharat Biotech today said there was no external pressure on the firm to speed up its development.

Nearly 50 million doses of Bharat Biotech's COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said.

A nasal vaccine against Covid-19, iNCOVACC, developed by Bharat Biotech, has been approved by India's Central Drugs Standard Control Organisation. This is India's first intra-nasal vaccine against Covid-19

Union Health Minister Dr Mansukh Mandaviya tweets that it's "a big boost to India's Fight against Covid-19"

Bharat Biotech International Ltd (BBIL) on Monday said it has completed the phase-III and booster dose trials for its intranasal Covid-19 vaccine BBV154, and it has proven to be safe.

Bharat Biotech on Friday said Japan has approved Covaxin booster dosage for travellers visiting the country.

Bharat Biotech, which is working on an intranasal COVID-19 vaccine candidate is hopeful of getting regulatory licenses this month, if all goes well, Chairman and Managing Director of BBIL, Krishna Ella said.